OCUL Ocular Therapeutix, Inc.

7.55
-0.38  -4.79%
Previous Close 7.93
Open 8.09
Price To book 3.17
Market Cap 187.84M
Shares 24,879,000
Volume 764,346
Short Ratio 6.85
Av. Daily Volume 891,661

SEC filingsSee all SEC filings

  1. 424B5 - Prospectus [Rule 424(b)(5)] 17541206
  2. 8-K - Current report 17539887
  3. 8-K - Current report 162051479
  4. 8-K - Current report 162023912
  5. 424B5 - Prospectus [Rule 424(b)(5)] 162023910

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released November 14, 2016. Primary endpoints met.
DEXTENZA
Post-surgical ocular inflammation and pain
Phase 3 trial did not meet primary endpoint - June 2016
DEXTENZA
Allergic conjunctivitis
Phase 3 initiated October 2016. Data due 1H 2018.
OTX-TP
Glaucoma and ocular hypertension
CRL July 25 2016 - due to manufacturing deficiencies. NDA resubmission announced January 23, 2017.
DEXTENZA
Ocular inflammation and pain following cataract surgery
Phase 2 complete. Assessing plans forward.
DEXTENZA
Dry Eye Disease

Latest News

  1. Ocular Therapeutix, Inc. Announces Public Offering of Common Stock
  2. OCULAR THERAPEUTIX, INC Files SEC form 8-K, Other Events
  3. 8:16 am Ocular Therapeutix announces that it has resubmitted a New Drug Application to the FDA for DEXTENZA (dexamethasone insert) 0.4 mg, for the treatment of ocular pain occurring after ophthalmic surgery
  4. Ocular Therapeutix™ Resubmits NDA for DEXTENZA™ for the Treatment of Ocular Pain Occurring After Ophthalmic Surgery
  5. ETFs with exposure to Ocular Therapeutix, Inc. : January 9, 2017
  6. 6 Major FDA Decisions and Biopharma Catalysts Coming in January and February
  7. Ocular (OCUL) Reports Positive Phase III Data on Eye Drug
  8. Ocular Therapeutix™ Announces Additional Successful Results for Phase 3 Clinical Trial of DEXTENZA™
  9. Ocular Therapeutix™ Announces Additional Successful Results for Phase 3 Clinical Trial of DEXTENZA™
  10. ETFs with exposure to Ocular Therapeutix, Inc. : December 30, 2016
  11. 7 Key FDA Decisions and Catalysts Expected in January and February
  12. How Ocular Therapeutix Inc (OCUL) Stacks Up Against Its Peers
  13. OCULAR THERAPEUTIX, INC Files SEC form 8-K, Other Events
  14. ETFs with exposure to Ocular Therapeutix, Inc. : December 8, 2016
  15. OCULAR THERAPEUTIX, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial State
  16. ETFs with exposure to Ocular Therapeutix, Inc. : November 28, 2016
  17. Ocular Therapeutix, Inc. :OCUL-US: Earnings Analysis: Q3, 2016 By the Numbers : November 23, 2016
  18. OCULAR THERAPEUTIX, INC Financials
  19. Ocular Therapeutix surges 14% on positive early clinical trial results
  20. Ocular Therapeutix™ Announces Successful Topline Results for Both Inflammation and Pain Primary Efficacy Endpoints from Phase 3 Clinical Trial of DEXTENZA™

SEC Filings

  1. 424B5 - Prospectus [Rule 424(b)(5)] 17541206
  2. 8-K - Current report 17539887
  3. 8-K - Current report 162051479
  4. 8-K - Current report 162023912
  5. 424B5 - Prospectus [Rule 424(b)(5)] 162023910
  6. CT ORDER - Confidential treatment order 162006883
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 161982778
  8. 8-K - Current report 161982770
  9. 8-K - Current report 161934056
  10. CT ORDER - Confidential treatment order 161859706